Pediatric Flecainide Pharmacogenomics: A Roadmap for Precision Care
Author Information
Author(s): Palmen Ronald, Walton Mollie, Wagner Jonathan
Primary Institution: University of Missouri-Kansas City School of Medicine
Hypothesis
What is the impact of genetic variation on the pharmacokinetics and pharmacodynamics of flecainide in pediatric patients?
Conclusion
Flecainide is effective for treating pediatric arrhythmias, but its narrow therapeutic index necessitates careful dosing based on genetic and developmental factors.
Supporting Evidence
- Flecainide is commonly used for treating tachyarrhythmias in children.
- Genetic variations can significantly affect how children metabolize flecainide.
- Current dosing guidelines for flecainide in children are often based on adult data.
Takeaway
Flecainide helps kids with heart rhythm problems, but doctors need to be careful with how much they give because kids' bodies process it differently than adults.
Methodology
This review outlines flecainide's disposition and response pathways and highlights opportunities for future research in pediatric pharmacogenomics.
Potential Biases
Potential bias due to reliance on existing literature and the limited number of pediatric studies.
Limitations
Limited data on pediatric pharmacokinetics and the impact of genetic variation on drug response.
Participant Demographics
Focus on pediatric patients, particularly those with supraventricular tachycardia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website